cyrilzakka/clinical-trials huggingface dataset:
Attitudes and Barriers of Prosthetics and Orthotics Professionals in Turkey Towards 3D Printers and Technology

This study aim is the attitudes and barriers of prosthetics and orthotics professionals towards 3D printers and technology will be determined.

It is known that there are generally concerns about high capital costs and return on investment in the use of 3D printer technology in Turkey.

It is known that there is no study in Turkey to investigate the attitudes and barriers of prosthetics and orthotics professionals towards 3D printers and technology. Therefore, the attitudes and barriers of prosthetics and orthotics professionals towards 3D printers and technology will be questioned in the study. It was aimed to reveal the perspectives and concerns about 3D printers and technology and to emphasize the importance of increasing the number of education and competent personnel regarding the dissemination of technological applications in practice.

In the study investigating the attitudes and barriers of prosthetics and orthosis professionals towards 3D printers and technology in Turkey, a total of 131 participants, 29 female and 102 male, aged at least 18 and at most 65 years old, were included.

The participants first filled out the Demographic Information Form. This form includes demographic information such as the participant's age, gender, education level, profession, duration of professional experience, geographical region where they work, the number of in-service trainings they receive in the field of orthosis and prosthesis, weekly working hours and the number of daily patients they communicate with.

At the end of the demographic information, the participants were asked to state open-endedly what they had concerns about technology that they could not define.

In addition, questions created according to the Technology Acceptance Model (TAM) and the Affinity for Technology Interaction (ATI) were also answered by the participants.

When the participants were asked whether they had concerns about 3D printers and technology that they could not define, it was determined that they mostly answered no. When the participants who had concerns were asked open-endedly about their concerns, the answers given were mostly about the lack of information or competent personnel for use when the answers were collected under common headings. It was observed that the technology acceptance model and proximity to technology had an effect on the time spent in the profession and the total score of ATI.

Eligibility Criteria:
Inclusion Criteria:

* As working in an Orthosis and Prosthesis Application Center
* Being 18 years of age or older.

Exclusion Criteria:

* Insufficient cognitive level to answer the survey
Pilot Investigation to Evaluate FlowOx2.0™ for Experimental Treatment of Spasticity

This is a descriptive, prospective, non-controlled clinical investigation to be conducted on approximately 10 enrolled subjects at one site at Haukeland University Hospital in Bergen, Norway. The target subjects are male or female, 18-70 years, diagnosed with MS according to revised McDonald criteria (9) with spasticity and pain associated with the spasticity. Spasticity is evaluated based on self-reported spasticity using the numerical rating scale (NRS) which describes the average score of spasticity over the last 24 hours at \>4 (where the scale scores spasticity from 0-10, where 0 is no spasticity, and 10 is worst possible spasticity), - combined with pain in the lower extremities last 24 hours. The pilot investigation is done to evaluate if FlowOx2.0™ can be used to treat spasticity with concomitant pain in patients with multiple sclerosis, using intermittent negative pressure affecting arteriovenous reflex.


Eligibility Criteria:
Inclusion Criteria:

1. Diagnose MS according to revised McDonald criteria
2. Give written informed consent.
3. Have an age between 18-70 years.
4. Have stable disease without attack or progression of loss of function in the last three months.
5. Have self-reported spasticity, scored using the numeric rating scale (NRS) which describes the average score of spasticity over the last 24 hours, at ≥ 4 (where the scale scores spasticity from 0-10, where 0 is no spasticity, and 10 is worst possible spasticity), - combined with pain in the lower extremities last 24 hours
6. Have tried standard treatment for spasticity and pain without achieving a satisfactory effect.
7. Stable and unchanged treatment of spasticity and pain the last month
8. Stable and unchanged disease-modulating treatment for MS last 6 months.
9. Function level measured by the Expanded Disability Status Scale (EDSS) 2.0-6.5
10. Can self-manage study equipment.

Exclusion Criteria:

1. Have spasticity due to a disease other than MS.
2. Pregnancy or plan a pregnancy within the upcoming study period of 6 months.
3. Have an ongoing infection.
4. Have received botulinum toxin injection for spasticity within the last 4 months.
5. Have symptoms or illness that make it difficult to participate in the study.
6. Having planned surgery or other treatment within the coming study period of 6 months makes it difficult to participate in the study.
7. Have functional scores outside inclusion criteria measured by EDSS 2.0-6.5
8. Have had disease activity beyond requirements for stable disease as described in inclusion criteria
9. Have changed drug treatment beyond requirements for stable treatment as described in inclusion criteria.
Study of Anlotinib in Patients With Soft Tissue Sarcoma（STS）(ALTER0203)

Compare the effects and safety of Anlotinib with placebo in patients with soft tissue sarcoma.


Eligibility Criteria:
Inclusion Criteria:

* Signed and dated informed consent
* Histological documentation of Soft Tissue Sarcoma,including Synovial sarcoma、Leiomyosarcoma、Alveolar soft part sarcoma、Undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma、Adipocytic Tumors、Fibrosarcoma、Clear cell sarcoma、Epithelioid sarcoma，With measurable disease.
* Within the past 6 months, using at least one failure of chemotherapy regimens (including anthracycline-based) in treating patients(except alveolar soft part sarcoma)
* 18-70years,ECOG PS:0-1,Life expectancy of more than 3 months
* Main organs function is normal
* The woman patients of childbearing age who must agree to take contraceptive methods (e.g. intrauterine device, contraceptive pill or condom) during the research and within another 6 months after it; who are not in the lactation period and examined as negative in blood serum test or urine pregnancy test within 7 days before the research; The man patients who must agree to take contraceptive methods during the research and within another 6 months after it

Exclusion Criteria:

* Prior treatment with Anlotinib
* With pleural effusion or ascites, cause respiratory syndrome
* Accepted the vascular endothelial growth inhibitor class targeted drug treatment of patients
* Plan to take systemic anti-tumor therapy within 4 weeks before grouping or during the medicine-taking period of this research, including Cytotoxic Therapy, Signal Transduction Inhibitor, and Immunotherapy (or who use Mitomycin C within 6 weeks before taking the treatment with experimental drug); The patients who have already taken Extended Field Radiotherapy (EF-RT) within 4 weeks before grouping or Limited Field Radiotherapy with proposed assessment of nidus within 2 weeks before grouping
* Symptoms of brain metastases cannot be controlled and treated within less than 2 months
* With severe and failed to controlled diseases
* Occurred venous thromboembolic events within 6 months
PRESTIGE Observational Study

Prestige artificial disc replacement is an alternative treatment option with 16 years of experience addressing the unmet needs of surgical fusion interventions. Previous studies on the PRESTIGE® cervical disc have proven the safety and effectiveness of artificial disc surgery with level I evidence.

The PRESTIGE Observational Study is intended to collect prospectively observational data primarily on the Quality of Life (QoL).

Degenerative cervical disc disease is associated with a very high burden to the patient and the society. If conservative treatment options fail, surgical interventions are the last treatment option.

Symptomatic disc degeneration leads to neck pain, which can radiate to the scapula and arm, with dumbness and tingling, and sometimes grasping and walking difficulties. At an advanced stage, muscle weakness can be observed in the nerve territory.

The quality of life and functionality of patients with therapy-resistant (conservatively treated) severe degeneration of the disc is greatly impaired, as they suffer from intense pain and thus disability. Patients of working age were significantly more impacted by their symptoms than older patients. They are no longer able to fully participate in everyday activities.

Cervical neck pain resulting from degenerative disc disease is associated with a major economic burden for payers.

Traditional cervical surgical decompressions and fusions are currently the most common treatment option. Despite good treatment success rates, fusions are associated with a negative impact on the normal kinematics of the spine, long recuperation times and long absence from work. Prestige artificial disc replacement is an alternative treatment option.

The PRESTIGE Observational Study is intended to collect information on Quality of Life (QoL) prior and after PRESTIGE® Cervical Disc surgery; data on pain prior of participation to the study, drug regiment and X-ray evaluation throughout the course of the study will be obtained. In addition adverse events and economic data will be documented.

Eligibility Criteria:
Inclusion Criteria:

* Patient must be willing to sign a Patient Data Release Form.
* Patient with degenerative disc disease (DDD) who is scheduled to receive a PRESTIGE® Cervical Disc and fulfills the indications according to the product description.

Exclusion Criteria:

* Patient fulfills any contraindication according to the product description.
* Patient has not reached the age of legal consent according to local laws.
* Patient has diabetes.
* Patient has Body Mass Index (BMI) \> 35.
* Patient has affected disc not between C3/C4 and C6/C7.
* Patient with instability of cervical spine.
* Patients who will receive extensive decompression.
Effect of Low-Dose Baclofen Administration on the GH-IGF1 Axis Study

Insulin-like growth factor I (IGF-I) is used as a measure of the body's ability to produce growth hormone. Growth hormone is important for muscle tissue as well as many other tissues in the body. Growth hormone (GH) and IGF-I have been shown to be reduced in many persons with SCI. Baclofen is a FDA approved drug that is used to treat spasticity. Persons receiving long-term baclofen therapy have been demonstrated to have increased growth hormone and IGF-I levels. IGF-I levels will be determined before and after treatment with baclofen. In this study, the investigators will determine the minimum dose of baclofen at which improvements in GH and IGF-1 levels occur.


Eligibility Criteria:
Inclusion Criteria:

* Patients with chronic SCI (injury greater than 6 months) who have been screened and found to have depressed plasma IGF-1 levels and who are not taking baclofen.

Exclusion Criteria:

* Acute illness of any etiology,
* Patients with chronic renal, liver, lung, or cardiac disease,
* Patients receiving any of the following medications: narcotics, or L-DOPA, and
* Alcoholics.
DINO RCT - Treating Anxiety in Children with Autism

Anxiety is prevalent in young children, under 7 years of age, with autism. Yet, few studies have examined anxiety interventions for this age range, and only one anxiety treatment study has included young children with cognitive and language delays. Anxiety treatment models utilizing cognitive-behavioral therapy (CBT), adapted for children with autism, are empirically supported in school-age autistic children. Further, preliminary evidence suggests CBT approaches may reduce intolerance of uncertainty (IU), a mechanistic construct that may contribute to the maintenance of anxiety in autistic children. This study seeks to address the existing gap in anxiety treatment by examining the feasibility and preliminary efficacy of a novel, telehealth CBT intervention, DINO Strategies for Anxiety and intolerance of Uncertainty Reduction (DINOSAUR), which targets both anxiety and IU in young autistic children.

The purpose of this study is to examine the feasibility and preliminary efficacy of a new treatment that targets both anxiety and IU, i.e., DINOSAUR, in young autistic children with varying cognitive and language levels. To accomplish this goal, we will investigate if DINOSAUR is a feasible intervention for families of young autistic children. We will also investigate if DINOSAUR is superior to an active control condition in reducing anxiety and IU. A third, exploratory goal is to understand how children's language and cognitive level affect their response to anxiety treatment. Seventy children, 4-6 years of age with autism and clinically significant anxiety, and their parents will be randomly assigned to receive either DINOSAUR or the active control (35 in each group) over 14 weeks via telehealth. Within each condition, children will be stratified based on cognitive level. Anxiety and IU will be assessed following treatment and at 4-month follow-up.

Eligibility Criteria:
Inclusion Criteria:

* Age 4 years 0 months to 6 years 11 months
* DSM-5 ASD diagnosis based on clinical impressions and results of the Autism Diagnostic Observation Schedule-2 (ADOS-2)
* CBCL Anxiety Problems T-score \> 65
* SB-5 ABIQ \> 60
* Receptive and expressive language age equivalent \> 36 months based on Test of Early Language Development, Fourth Edition (TELD-4)
* Parent (or other caregiver) available and willing to attend 14-week intervention
* Absence of identifiable neurological (e.g., epilepsy), genetic (e.g., Down syndrome, fragile X, tuberous sclerosis, neurofibromatosis) or severe sensory-motor (e.g., severe vision impairment) conditions
* Able to walk independently (a requirement for ADOS-2)

Exclusion Criteria:

* Primary language other than English
* Child is in foster care
* Child displays severe behavior challenges that prevent participation in treatment groups (i.e., severe tantrums, aggression, or self-injury)
* Participating parent experiencing active symptoms of substance abuse or severe mental illness (i.e., schizophrenia, bipolar disorder)
CAPRELSA® REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa®) in Current Clinical Practice

In this registry it is planned to include all Belgian patients diagnosed with aggressive and symptomatic unresectable locally advanced or metastatic Medullary Thyroid Cancer (MTC) who have been prescribed Caprelsa® (vandetanib).

The characteristics of patients receiving Caprelsa® (vandetanib) will be described. Therefore real life data regarding demographic characteristics, evolution of the disease, RET mutation status, the treatment before, during and after vandetanib, dose and duration of treatment with Caprelsa® (vandetanib) and time of progression or death (if applicable) will be included.


Eligibility Criteria:
Inclusion criteria

The subject population that will be observed in this registry, must fulfil all of the following criteria:

1. Provision of subject Informed Consent
2. Patients diagnosed with aggressive and symptomatic unresectable locally advanced or metastatic MTC
3. Patients who already received a prescription for vandetanib in accordance with the scientific leaflet and fulfilling the reimbursement criteria of vandetanib and who are currently treated or have been treated with vandetanib 100 mg or 300 mg tablets.

The prescription of the medicinal product is clearly separated from the decision to include the subject in the registry.

Exclusion criteria Not applicable since patients participating in another study can take part in this registry.
Measles, Mumps, and Rubella (MMR) Immunity in College Students

This study will lay the foundation for determining the underlying reasons for lack of immunity to mumps that led to the 2006 mumps outbreak on college campuses in the Mid West, and it will assess the potential for similar outbreaks of measles and rubella. A total of 70 to 80 college students (age 18 to 22) on the Emory campus (or nearby college campuses or the community) will be assessed for antibodies to measles, mumps or rubella by drawing a one-time blood sample. Their medical records will be verified for documentation of immunization with MMR vaccine prior to enrollment in the study. If a study volunteer is found to not have MMR immunity, they will be offered an MMR-II vaccine. For this group, additional blood specimens will be obtained.

No additional description needed.

Eligibility Criteria:
Inclusion Criteria:

* Ability and willing to provide an informed consent
* Documented receipt of MMR-II vaccination in childhood
* Not pregnant

Exclusion Criteria

* No history of HIV infection.
* Immunocompromised health status due to HIV infection, cancer, diabetes, liver, lung or kidney diseases, autoimmune diseases, history of splenectomy.
* Use of immunosuppressive medications within last 2 to 3 months (oral or parenteral corticosteroids or cytotoxic medications)
* Medical conditions that require the use of immunosuppressive medications
* Received blood or blood products within the last 30 days
* Any vaccines received in the last 30 days
Effects of Kinesio Taping and Extracorporeal Shock Wave Therapy in the Calcaneal Spur

The term \&#34;heel pain\&#34; is used to describe a common, painful condition that is localized in the plantar part of the heel and worsens when weight is placed on the heel. Patients with heel pain are more likely to have thickened plantar fascia, abnormal plantar fascia tissue, thicker plantar heel fat pad, and calcaneal spur. Calcaneal spurs are bony protrusions that typically occur just in front of the medial calcaneal tuberosity. Systemic medical treatments, physical therapy agents, exercise and local injections are often applied for heel pain caused by plantar fasciitis and calcaneal spur.

This study is to examine the effects of ESWT and kinesio taping on pain and other clinical outcomes in patients with calcaneal spurs.

The responses of patients who underwent ESWT or kinesio taping due to calcaneal spur before and after treatment will be compared. Pain, functionality and quality of life are the clinical parameters compared.

Eligibility Criteria:
Inclusion Criteria:

* Aged 18 years and over with heel pain
* A calcaneal spur seen on foot radiographs

Exclusion Criteria:

* Those who had received a steroid injection into the heel within the past three months
* Those who had experienced trauma or surgery to the foot and ankle within the past six months
* Those with a rheumatic disease affecting the foot and ankle (e.g., spondyloarthritis)
* Those with open wounds or infections in the area to be treated with lesions.
Phase 2 Pilot Study to Evaluate the Safety and Efficacy of RM-131 Administered to Females With Anorexia Nervosa

The purpose of this study is to determine if administration of RM-131 is effective in improving appetite and gastrointestinal symptoms leading to the recovery of patients with anorexia nervosa in the outpatient setting.


Eligibility Criteria:
Inclusion Criteria:

* DSM-IV criteria for anorexia nervosa, including weight \<85% of ideal body weight (IBW) and amenorrhea for three months;
* Age 18-45 years old;
* Gastrointestinal tract symptoms;
* Non-hormonal method of birth control, which must be used throughout the study. Female patients unable to bear children must have this documented (i.e., tubal ligation, hysterectomy, or post-menopausal, defined as a minimum of one year since the last menstrual period and elevated FSH);
* Stable concomitant medications defined as no changes in regimen for at least 2 weeks prior to baseline;
* Able to provide written informed consent prior to any study procedures and be willing and able to comply with study procedures, including daily SC injections and completion of a daily injection log.
* Patient has a primary care physician or treatment team managing her care.

Exclusion Criteria:

* Use of hormone therapy (including but not limited to estrogen, progesterone) or hormonal methods of birth control (i.e., oral, implantable, or injectable) within eight weeks of screening; or Depo-Provera within six months of screening;
* Pregnancy, lactation or breastfeeding, or a positive serum or urine pregnancy test, within eight weeks of screening;
* History of diabetes mellitus;
* History of purging behaviors greater than once monthly within the last three months;
* Active substance abuse;
* Use of metoclopramide, erythromycin, 5HT3 anti-emetics, or opioid medications within 2 weeks prior to baseline. \[Note: these drugs should also not be used post-baseline\];
* Hematocrit \< 30.0 %, hemoglobin \< 10.0 g/dl, potassium \< 3.0 mmol/L, fasting glucose \> 100 mg/dL, creatinine \> 1.5 mg/dL, AST or ALT \> 1.5 times the upper limit of normal, or abnormal plasma thyroid stimulating hormone (TSH) level;
* Currently receiving parenteral feeding or enteral feeding, or presence of a nasogastric or other enteral tube for feeding or decompression;
* History of gastric surgery such as fundoplication, gastrectomy, gastric pacemaker placement, vagotomy, bariatric procedure, small or large bowel resection;
* Clinical suspicion, in the opinion of the investigator, of active or symptomatic peptic ulcer disease, cholelithiasis, colitis, celiac sprue, or inflammatory bowel disease;
* Active suicidal ideation;
* Beck Depression Inventory-2 score of ≥ 29;
* Current inpatient hospitalization;
* Allergic or intolerant of egg, milk, wheat or algae, as these are components of the GEBT test meal;
* Participation in a clinical study with an investigational medication or device within the 30 days prior to dosing in the present study;
* Any other reason, which in the opinion of the Investigator, including severe renal, hepatic or cardiac disease, would confound proper interpretation of the study or expose a patient to unacceptable risk.
Emergency Room Visits and Older Patients (ER2)

Today's population is living longer than prior generations. Senior patients, defined as 65 years or older, are therefore increasing in number, and representing a larger number of hospitalized patients. Thus, assessing and addressing the needs of the growing number of older ER users is essential. The overall objective of the study is to examine the feasibility and the epidemiology of two screening tools ("Programme de Recherche sur l'Intégration des Services pour le Maintien de l'Autonomie" (PRISMA-7) and Emergency Room Evaluation and recommendations (ER2)) used in the Emergency Room of Jewish General Hospital to screen older patients (i.e.; ≥65 years) at risk of adverse health events. A prospective observational cohort design will be used for the study's two phases; phase 1- assessment and phase 2- assessment as well as recommendations.


Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 65 years.
* Unplanned ER visits.

Exclusion Criteria:

* Death within the 24 hours of first visiting ER.
* Palliative care due to ER visit.